Gestational Diabetes Mellitus (GDM)MyGlucoCareNCT07372872
Feasibility Testing of the "MyGlucoCare" Smartphone App for Women With Gestational Diabetes
A study testing MyGlucoCare in people with Gestational Diabetes Mellitus (GDM), run by Hong Kong Metropolitan University at 1 site in Hong Kong.
Trial summary
The goal of this pilot study is to test the feasibility and preliminary impact of "MyGlucoCare," a smartphone-based program designed to support women with gestational diabetes (GDM). Read more about this study
- Who is it for?
- Ages 18 years and older, women only
- Conditions the study is for
- Gestational Diabetes Mellitus (GDM)
- What is being tested?
- MyGlucoCare
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 30 participants
- Where
- 1 siteHong Kong
- Study dates
- 1 May 2026to 30 Nov 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- Women only
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Pregnant women diagnosed with Gestational Diabetes Mellitus (GDM) via a 75g Oral Glucose Tolerance Test (OGTT), conducted between 24 and 28 weeks of gestation (Hong Kong College of Obstetricians and Gynaecologists, 2016).
- Aged 18 years or older.
- Own a smartphone with reliable internet access.
- Able to read and understand Chinese.
Who cannot join
- Pre-existing diagnosis of Type 1 or Type 2 diabetes mellitus.
- Known major fetal anomaly.
- Concurrent enrollment in any other structured GDM self-management intervention.
- Severe mental health conditions.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Hong Kong1 site, 1 recruiting
- Recruiting
Hong Kong Metropolitan University
Hong Kong
Bronya Luk, DHSc, 39708758, bluk@hkmu.edu.hk
About this study
Official title: Development and Feasibility Testing of the "MyGlucoCare" Smartphone-Based Self-Management for Personalised Support of Women With Gestational Diabetes
The goal of this pilot study is to test the feasibility and preliminary impact of "MyGlucoCare," a smartphone-based program designed to support women with gestational diabetes (GDM). The main questions it aims to answer are:
Is the "MyGlucoCare" program practical and acceptable for participants?
Read more
Does it show preliminary signs of improving self-management, blood sugar control, and well-being in women with gestational diabetes (GDM)?
Researchers will conduct a single-arm study to gather initial data on the program's use and effects, which will be used to plan a larger future clinical trial.
Participants will:
Use the "MyGlucoCare" app for 8-12 weeks during their pregnancy.
Receive personalized education, support from a clinician, and access to a moderated peer group through the app.
Complete questionnaires and log health data via the app at the start, near the end of pregnancy, and after giving birth.
Some participants will also take part in an interview to share their feedback on the program.
Read the detailed description
- Project Objectives The objective of this pilot study is to evaluate the feasibility, acceptability, and preliminary impact of the "MyGlucoCare" smartphone program, which provides holistic self-management support for women with gestational diabetes mellitus (GDM). The primary aim is to determine the feasibility of the research procedures and the acceptability of the "MyGlucoCare" program itself. This will involve assessing participant recruitment, retention, and data completion rates to evaluate feasibility. The program's acceptability and usability will be evaluated from the participants' perspective by measuring their engagement and subjective experiences. The secondary aim is to gather preliminary evidence of the program's potential impact. This includes obtaining initial estimates of its effect on self-efficacy for diabetes management and self-reported self-management behaviours. The study will also explore preliminary changes in key clinical and behavioural markers, specifically glycemic control (measured by pre- and post-meal blood glucose levels), physical activity levels, and perceived stress levels. Finally, a descriptive exploration of relevant maternal and neonatal pregnancy outcomes will be conducted to inform future research.
- Project Plan and Methodology Study Design: A single-arm pilot study with a pre-test/post-test design. Sample Size A pragmatic sample of 30 women will be recruited. This sample size is consistent with recommendations for pilot studies to obtain reliable estimates of feasibility parameters and is not intended for formal hypothesis testing. Recruitment Strategy A multi-faceted strategy will ensure timely participant enrolment. This will consist of community-based recruitment using targeted advertisements on Hong Kong parenting forums and social media, supplemented by snowball sampling. Eligibility Criteria Eligible participants will be pregnant women diagnosed with GDM via a 75g Oral Glucose Tolerance Test (OGTT), conducted between 24 and 28 weeks of gestation. Participants must be aged 18 years or older, own a smartphone with reliable internet access, and be able to read and understand Chinese. Potential participants will be excluded from the study if they have a pre-existing diagnosis of Type 1 or Type 2 diabetes mellitus, a known major fetal anomaly, or are concurrently enrolled in any other structured GDM self-management intervention. Individuals with severe mental health conditions that could impair their ability to use the technology-based intervention will also be excluded. The "MyGlucoCare" Intervention The "MyGlucoCare" intervention is a comprehensive, technology-facilitated program delivered over 8 to 12 weeks. It integrates three core components to provide holistic and personalised support for women with GDM. Component A: Personalised Education \& Skill-Building (Automated) This component delivers a structured curriculum through automated messages and posts within the MyGlucoCare platform. The educational content covers essential topics for gestational diabetes (GDM) management, including disease education, dietary guidance using food exchange tables, safe exercise routines, stress management techniques, community resource information, advice for dining out, supporting services for pregnant mothers, and postpartum planning information encompassing breastfeeding and newborn care. Component B: Proactive Personalised Support (Driven by Clinicians) A dedicated study nurse or midwife provides individualised clinical support through the MyGlucoCare platform. Support is delivered via two primary methods: proactive, scheduled check-ins and responsive communication. The clinician will initiate bi-weekly contact to review glucose logs, identify personal barriers to self-management, and collaboratively set individualised goals. Furthermore, participants can use the platform's chat function to ask questions at any time, receiving a response from the clinician within 24 hours on weekdays. Component C: Facilitated Peer Support (Moderated) To foster a sense of community and shared experience, a private peer support group will be established using an integrated chat function. This group will be lightly moderated by the research team to encourage the exchange of experiences and practical tips while maintaining a safe, positive, and supportive environment for all participants. Data Collection \& Measures Data will be collected at three time points: Baseline (T0), post-intervention (T1, at approximately 36 weeks' gestation), and Postpartum (T2, 6-12 weeks after delivery). Data collection will be facilitated through the MyGlucoCare platform, and participant interviews. Feasibility Metrics will be systematically tracked and include screening logs to determine recruitment rates, study completion data to calculate retention rates, adherence to scheduled support calls, and quantitative engagement metrics with the platform's chat features. Acceptability \& Usability will be assessed using a mixed-methods approach. Quantitatively, the standardized 10-item System Usability Scale (SUS) will be administered. Qualitatively, semi-structured interviews will be conducted with a sub-sample of approximately 10 participants to explore their experiences, the perceived usefulness of the program, and to gather detailed suggestions for improvement. Preliminary Outcome Measures will be collected to inform a future definitive trial. These include:
- Self-Efficacy for Diabetes Management measured using the Diabetes Management Self-Efficacy Scale.
- Self-Management Behaviours, assessed with a Diabetes Self-Management Questionnaire (SDSCA).
- Glycaemic Control, evaluated through self-monitored pre-meal and 2-hour post-meal blood glucose levels (between T0 and T1) and the results of a postpartum Oral Glucose Tolerance Test (OGTT) at T2.
- Psychological Well-being measured using the Patient Health Questionnaire-9 (PHQ-9).
- Participant-Reported pregnancy outcomes: Maternal and Infant Outcomes, collected from medical records at T2. Data Analysis Quantitative Analysis: Descriptive statistics (means, frequencies, standard deviations) will be used for feasibility outcomes and participant characteristics. Pre-post changes in outcome measures will be analysed using paired t-tests or Wilcoxon signed-rank tests, with a focus on estimating effect sizes and confidence intervals for future sample size calculation. Qualitative Analysis: Thematic analysis will be applied to the interview transcripts to identify key themes related to acceptability and suggestions for refinement. Ethical Considerations Ethical approval has been obtained from the HKMU Research ethical committee. Written informed consent will be obtained from all participants. All data will be anonymized and stored securely. Confidentiality within the peer group will be emphasized in the group rules.
- Expected Outputs or Deliverables
This pilot study will generate essential deliverables to support future research and implementation:
- A Validated "MyGlucoCare" Intervention Protocol: A ready-to-use package including the educational curriculum, clinician support guidelines, and peer moderation framework, refined through user feedback.
- Feasibility and Acceptability Evidence: A clear report quantifying recruitment, retention, and engagement rates, alongside participant feedback on usability and satisfaction, to determine the viability of a full-scale trial.
- Preliminary Efficacy Data for RCT Planning: Initial data on changes in self-efficacy, self-management, and glycaemic control will inform the sample size calculation and methodology for a definitive randomized controlled trial. Crucially, these findings will directly address reviewer comments on the submitted FDS proposal (UGC/FDS16/M27/25) regarding the need for pilot data, thereby strengthening the revised application and increasing its chance of success in the next resubmission round.
- To ensure broad impact, the findings will be actively disseminated. A minimum of one manuscript is planned for submission to high-impact, peer-reviewed journals, such as JMIR Diabetes for primary outcomes on usability and acceptance. Preliminary results will be presented at international conferences, including the East Asian Forum of Nursing Scholars and the International Congress on Midwifery. Furthermore, findings will be shared with local healthcare partners to facilitate translation into clinical practice.
- Conditions
- Gestational Diabetes Mellitus (GDM)
- Being tested
- MyGlucoCare
- Keywords
- GDM, Smartphone-Based Self-Management, Personalised Support
- Medical subject headings
- Diabetes, Gestational
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
MyGlucoCareDevice
The "MyGlucoCare" intervention is a comprehensive, technology-facilitated program delivered over 8 to 12 weeks. It integrates three core components to provide holistic and personalised support for women with gestational diabetes (GDM).
| Study group | Role | What they receive |
|---|---|---|
| "MyGlucoCare" intervention | Experimental | The "MyGlucoCare" intervention is a comprehensive, technology-facilitated program delivered over 8 to 12 weeks. Receives: Device: MyGlucoCare |
What is being measured
The primary outcome is the main question the study is designed to answer.
Enagagement
Measures participant interaction with the study protocol and app (%). • Measures: Mean/median frequency of (e.g., per week)
Measured: 8-12 weeks
Recruitment & Retention Rates
Assesses the practicality of executing the trial. • Unit of Measure: Proportion/Percentage (%) for each
Measured: 8-12 weeks
System Usability
Quantifies the perceived usability of the "MyGlucoCare" app using a validated instrument.• Measure: Mean score on the System Usability Scale (SUS). • Unit of Measure: Score on a scale (0-100).
Measured: 8-12 weeks
Secondary outcomes (1)
Secondary outcome measures
Change in Diabetes Management Self-Efficacy Score (DMSES, 20-200; higher=better).
Change in Diabetes Self-Care Activities frequency (SDSCA, 0-7 days/week; higher=better).
Change in Self-Monitored Blood Glucose (fasting \& postprandial mmol/L; lower=better).
Postpartum Glucose Tolerance Status (% with normal OGTT at 6-12 weeks postpartum).
Change in Depressive Symptom Score (PHQ-9, 0-27; higher=worse). Maternal and Neonatal Delivery Outcomes: gestational age, mode of delivery, birth weight, and neonatal hypoglycemia.
Measured: All changes measured from baseline (T0) to post-intervention (T1, 8-12 weeks), except postpartum OGTT and delivery outcomes collected at T2 (postpartum period).
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted28 Jan 2026
- Study start1 May 2026
- Primary completion30 Nov 2026 (estimated)
- Study completion30 Nov 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (8)Papers the sponsor has linked to this study.
- Other trials for Gestational Diabetes Mellitus (GDM)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 30 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Hong Kong Metropolitan University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Dr Bronya LUK Hi Kwan, Hong Kong Metropolitan University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07372872
- Sponsor's protocol ID
- PFDS/2025/21
- Other IDs
- PFDS/2025/21
- Acronym
- MyGlucoCare
- Status last verified
- May 2026
- First submitted
- 12 Jan 2026
- Last updated
- 22 May 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: The study is conducted under ethical approval which, along with the participant consent forms, does not include provisions for public sharing of individual-level data. Sharing IPD would violate the confidentiality agreement with our participants. Aggregated data will be presented in publications.
Publications
Wang, Y., Lei, T., & Liu, X. (2020). Chinese System Usability Scale: Translation, Revision, Psychological Measurement. International Journal of Human-Computer Interaction, 36(10), 953-963. https://doi.org/10.1080/10447318.2019.1700644
Toobert DJ, Hampson SE, Glasgow RE. The summary of diabetes self-care activities measure: results from 7 studies and a revised scale. Diabetes Care. 2000 Jul;23(7):943-50. doi: 10.2337/diacare.23.7.943.
PubMed 10895844Ritter PL, Lorig K, Laurent DD. Characteristics of the Spanish- and English-Language Self-Efficacy to Manage Diabetes Scales. Diabetes Educ. 2016 Apr;42(2):167-77. doi: 10.1177/0145721716628648. Epub 2016 Feb 4.
PubMed 26846336O'Neill B. Sample size determination with a pilot study. PLoS One. 2022 Feb 15;17(2):e0262804. doi: 10.1371/journal.pone.0262804. eCollection 2022.
PubMed 35167592Lorig, K. R., Ritter, P. L., & González, V. M. (2003). Nursing Research (Vol. 52, Issue 6). http://journals.lww.com/nursingresearchonline
Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001 Sep;16(9):606-13. doi: 10.1046/j.1525-1497.2001.016009606.x.
PubMed 11556941Hong Kong College of Obstetricians and Gynaecologists. (2016). HKCOG Guidelines Guidelines for the Management of Gestational Diabetes Mellitus.
Jordan, P. W., Thomas, B., McClelland, I. L., & Weerdmeester, B. (1996). Usability evaluation in industry. CRC press
Study at a glance
From the registry record, last updated by the sponsor on 22 May 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Development and Feasibility Testing of the "MyGlucoCare" Smartphone-Based Self-Management for Personalised Support of Women With Gestational Diabetes
- ClinicalTrials.gov ID
- NCT07372872
- Acronym / sponsor ID
- MyGlucoCare / PFDS/2025/21
- Conditions
- Gestational Diabetes Mellitus (GDM)
- Keywords
- GDM, Smartphone-Based Self-Management, Personalised Support
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 30 participants (estimated)
- Lead sponsor
- Hong Kong Metropolitan UniversityUniversity, hospital or other
- Study start
- 1 May 2026 (actual)
- Primary completion
- 30 Nov 2026 (estimated)
- Study completion
- 30 Nov 2026 (estimated)
- First posted
- 28 Jan 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this pilot study is to test the feasibility and preliminary impact of "MyGlucoCare," a smartphone-based program designed to support women with gestational diabetes (GDM). The main questions it aims to answer are:
Is the "MyGlucoCare" program practical and acceptable for participants?
Does it show preliminary signs of improving self-management, blood sugar control, and well-being in women with gestational diabetes (GDM)?
Researchers will conduct a single-arm study to gather initial data on the program's use and effects, which will be used to plan a larger future clinical trial.
Participants will:
Use the "MyGlucoCare" app for 8-12 weeks during their pregnancy.
Receive personalized education, support from a clinician, and access to a moderated peer group through the app.
Complete questionnaires and log health data via the app at the start, near the end of pregnancy, and after giving birth.
Some participants will also take part in an interview to share their feedback on the program.
Detailed description
- Project Objectives The objective of this pilot study is to evaluate the feasibility, acceptability, and preliminary impact of the "MyGlucoCare" smartphone program, which provides holistic self-management support for women with gestational diabetes mellitus (GDM). The primary aim is to determine the feasibility of the research procedures and the acceptability of the "MyGlucoCare" program itself. This will involve assessing participant recruitment, retention, and data completion rates to evaluate feasibility. The program's acceptability and usability will be evaluated from the participants' perspective by measuring their engagement and subjective experiences. The secondary aim is to gather preliminary evidence of the program's potential impact. This includes obtaining initial estimates of its effect on self-efficacy for diabetes management and self-reported self-management behaviours. The study will also explore preliminary changes in key clinical and behavioural markers, specifically glycemic control (measured by pre- and post-meal blood glucose levels), physical activity levels, and perceived stress levels. Finally, a descriptive exploration of relevant maternal and neonatal pregnancy outcomes will be conducted to inform future research.
- Project Plan and Methodology Study Design: A single-arm pilot study with a pre-test/post-test design. Sample Size A pragmatic sample of 30 women will be recruited. This sample size is consistent with recommendations for pilot studies to obtain reliable estimates of feasibility parameters and is not intended for formal hypothesis testing. Recruitment Strategy A multi-faceted strategy will ensure timely participant enrolment. This will consist of community-based recruitment using targeted advertisements on Hong Kong parenting forums and social media, supplemented by snowball sampling. Eligibility Criteria Eligible participants will be pregnant women diagnosed with GDM via a 75g Oral Glucose Tolerance Test (OGTT), conducted between 24 and 28 weeks of gestation. Participants must be aged 18 years or older, own a smartphone with reliable internet access, and be able to read and understand Chinese. Potential participants will be excluded from the study if they have a pre-existing diagnosis of Type 1 or Type 2 diabetes mellitus, a known major fetal anomaly, or are concurrently enrolled in any other structured GDM self-management intervention. Individuals with severe mental health conditions that could impair their ability to use the technology-based intervention will also be excluded. The "MyGlucoCare" Intervention The "MyGlucoCare" intervention is a comprehensive, technology-facilitated program delivered over 8 to 12 weeks. It integrates three core components to provide holistic and personalised support for women with GDM. Component A: Personalised Education \& Skill-Building (Automated) This component delivers a structured curriculum through automated messages and posts within the MyGlucoCare platform. The educational content covers essential topics for gestational diabetes (GDM) management, including disease education, dietary guidance using food exchange tables, safe exercise routines, stress management techniques, community resource information, advice for dining out, supporting services for pregnant mothers, and postpartum planning information encompassing breastfeeding and newborn care. Component B: Proactive Personalised Support (Driven by Clinicians) A dedicated study nurse or midwife provides individualised clinical support through the MyGlucoCare platform. Support is delivered via two primary methods: proactive, scheduled check-ins and responsive communication. The clinician will initiate bi-weekly contact to review glucose logs, identify personal barriers to self-management, and collaboratively set individualised goals. Furthermore, participants can use the platform's chat function to ask questions at any time, receiving a response from the clinician within 24 hours on weekdays. Component C: Facilitated Peer Support (Moderated) To foster a sense of community and shared experience, a private peer support group will be established using an integrated chat function. This group will be lightly moderated by the research team to encourage the exchange of experiences and practical tips while maintaining a safe, positive, and supportive environment for all participants. Data Collection \& Measures Data will be collected at three time points: Baseline (T0), post-intervention (T1, at approximately 36 weeks' gestation), and Postpartum (T2, 6-12 weeks after delivery). Data collection will be facilitated through the MyGlucoCare platform, and participant interviews. Feasibility Metrics will be systematically tracked and include screening logs to determine recruitment rates, study completion data to calculate retention rates, adherence to scheduled support calls, and quantitative engagement metrics with the platform's chat features. Acceptability \& Usability will be assessed using a mixed-methods approach. Quantitatively, the standardized 10-item System Usability Scale (SUS) will be administered. Qualitatively, semi-structured interviews will be conducted with a sub-sample of approximately 10 participants to explore their experiences, the perceived usefulness of the program, and to gather detailed suggestions for improvement. Preliminary Outcome Measures will be collected to inform a future definitive trial. These include:
- Self-Efficacy for Diabetes Management measured using the Diabetes Management Self-Efficacy Scale.
- Self-Management Behaviours, assessed with a Diabetes Self-Management Questionnaire (SDSCA).
- Glycaemic Control, evaluated through self-monitored pre-meal and 2-hour post-meal blood glucose levels (between T0 and T1) and the results of a postpartum Oral Glucose Tolerance Test (OGTT) at T2.
- Psychological Well-being measured using the Patient Health Questionnaire-9 (PHQ-9).
- Participant-Reported pregnancy outcomes: Maternal and Infant Outcomes, collected from medical records at T2. Data Analysis Quantitative Analysis: Descriptive statistics (means, frequencies, standard deviations) will be used for feasibility outcomes and participant characteristics. Pre-post changes in outcome measures will be analysed using paired t-tests or Wilcoxon signed-rank tests, with a focus on estimating effect sizes and confidence intervals for future sample size calculation. Qualitative Analysis: Thematic analysis will be applied to the interview transcripts to identify key themes related to acceptability and suggestions for refinement. Ethical Considerations Ethical approval has been obtained from the HKMU Research ethical committee. Written informed consent will be obtained from all participants. All data will be anonymized and stored securely. Confidentiality within the peer group will be emphasized in the group rules.
- Expected Outputs or Deliverables
This pilot study will generate essential deliverables to support future research and implementation:
- A Validated "MyGlucoCare" Intervention Protocol: A ready-to-use package including the educational curriculum, clinician support guidelines, and peer moderation framework, refined through user feedback.
- Feasibility and Acceptability Evidence: A clear report quantifying recruitment, retention, and engagement rates, alongside participant feedback on usability and satisfaction, to determine the viability of a full-scale trial.
- Preliminary Efficacy Data for RCT Planning: Initial data on changes in self-efficacy, self-management, and glycaemic control will inform the sample size calculation and methodology for a definitive randomized controlled trial. Crucially, these findings will directly address reviewer comments on the submitted FDS proposal (UGC/FDS16/M27/25) regarding the need for pilot data, thereby strengthening the revised application and increasing its chance of success in the next resubmission round.
- To ensure broad impact, the findings will be actively disseminated. A minimum of one manuscript is planned for submission to high-impact, peer-reviewed journals, such as JMIR Diabetes for primary outcomes on usability and acceptance. Preliminary results will be presented at international conferences, including the East Asian Forum of Nursing Scholars and the International Congress on Midwifery. Furthermore, findings will be shared with local healthcare partners to facilitate translation into clinical practice.
Study design
- Primary purpose
- Other
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| "MyGlucoCare" intervention | Experimental | Device: MyGlucoCareThe "MyGlucoCare" intervention is a comprehensive, technology-facilitated program delivered over 8 to 12 weeks. |
Who may qualify
- Ages
- 18 years and older
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- Pregnant women diagnosed with Gestational Diabetes Mellitus (GDM) via a 75g Oral Glucose Tolerance Test (OGTT), conducted between 24 and 28 weeks of gestation (Hong Kong College of Obstetricians and Gynaecologists, 2016).
- Aged 18 years or older.
- Own a smartphone with reliable internet access.
- Able to read and understand Chinese.
Key exclusion criteria (4 listed)
- Pre-existing diagnosis of Type 1 or Type 2 diabetes mellitus.
- Known major fetal anomaly.
- Concurrent enrollment in any other structured GDM self-management intervention.
- Severe mental health conditions.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| MyGlucoCareThe "MyGlucoCare" intervention is a comprehensive, technology-facilitated program delivered over 8 to 12 weeks. It integrates three core components to provide holistic and personalised support for women with gestational diabetes (GDM). | Device | "MyGlucoCare" intervention |
Primary outcome
Enagagement
Time frame: 8-12 weeks
Measures participant interaction with the study protocol and app (%). • Measures: Mean/median frequency of (e.g., per week)
Recruitment & Retention Rates
Time frame: 8-12 weeks
Assesses the practicality of executing the trial. • Unit of Measure: Proportion/Percentage (%) for each
System Usability
Time frame: 8-12 weeks
Quantifies the perceived usability of the "MyGlucoCare" app using a validated instrument.• Measure: Mean score on the System Usability Scale (SUS). • Unit of Measure: Score on a scale (0-100).
1 secondary outcome
Secondary outcome measures
Time frame: All changes measured from baseline (T0) to post-intervention (T1, 8-12 weeks), except postpartum OGTT and delivery outcomes collected at T2 (postpartum period).
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 22 May 2026.
- Results publicationWang, Y., Lei, T., & Liu, X. (2020). Chinese System Usability Scale: Translation, Revision, Psychological Measurement. International Journal of Human-Computer Interaction, 36(10), 953-963. https://doi.org/10.1080/10447318.2019.1700644
- Results publication: PubMed 10895844Toobert DJ, Hampson SE, Glasgow RE. The summary of diabetes self-care activities measure: results from 7 studies and a revised scale. Diabetes Care. 2000 Jul;23(7):943-50. doi: 10.2337/diacare.23.7.943.
- Results publication: PubMed 26846336Ritter PL, Lorig K, Laurent DD. Characteristics of the Spanish- and English-Language Self-Efficacy to Manage Diabetes Scales. Diabetes Educ. 2016 Apr;42(2):167-77. doi: 10.1177/0145721716628648. Epub 2016 Feb 4.
- Results publication: PubMed 35167592O'Neill B. Sample size determination with a pilot study. PLoS One. 2022 Feb 15;17(2):e0262804. doi: 10.1371/journal.pone.0262804. eCollection 2022.
- Results publicationLorig, K. R., Ritter, P. L., & González, V. M. (2003). Nursing Research (Vol. 52, Issue 6). http://journals.lww.com/nursingresearchonline
- Results publication: PubMed 11556941Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001 Sep;16(9):606-13. doi: 10.1046/j.1525-1497.2001.016009606.x.
- Results publicationHong Kong College of Obstetricians and Gynaecologists. (2016). HKCOG Guidelines Guidelines for the Management of Gestational Diabetes Mellitus.
- Results publicationJordan, P. W., Thomas, B., McClelland, I. L., & Weerdmeester, B. (1996). Usability evaluation in industry. CRC press
- Individual participant dataSharing planned: No. The study is conducted under ethical approval which, along with the participant consent forms, does not include provisions for public sharing of individual-level data. Sharing IPD would violate the confidentiality agreement with our participants. Aggregated data will be presented in publications.
Related trials for Gestational Diabetes Mellitus (GDM)
Active, not recruiting
Effect of Probiotics on Insulin Sensitivity in Overweight and Obese Pregnancy
Obesity & Overweight, Gestational Diabetes Mellitus (GDM)
Not yet recruitingObservational study
Ultrasound Assessment Of Gastric Volume In Pregnant Women Undergoing Elective Cesarean Section
Gestational Diabetes Mellitus (GDM), Obstetric Anesthesia
Active, not recruitingPhase 2
Effectiveness Study of a Lifestyle Intervention Versus Metformin in Mothers With Recent Gestational Diabetes
Weight Loss, Gestational Diabetes Mellitus in Pregnancy
Not yet recruiting
STRONG: SMART Trial
Gestational Diabetes Mellitus (GDM)
Not yet recruiting
A Study to Lower Blood Pressure One Year After Childbirth in Women Who Had Preeclampsia
Adverse Pregnancy Outcomes, Cardiovascular Diseases
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing MyGlucoCare in people with Gestational Diabetes Mellitus (GDM), run by Hong Kong Metropolitan University at 1 site in Hong Kong.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 22 May 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Hong Kong. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Bronya Luk Assistant Professor, DHSc, MN, BN (+852 39708758, bluk@hkmu.edu.hk), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Enagagement (time frame: 8-12 weeks). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07372872, which also lists 8 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 May 2026.